“…In that way, one third of the injected dose is cleared from plasma into 3-4 h, the remaining being capable of circulating in the blood with a t 1/2 of 44-55 h; it is preferentially accumulated into the tumor environment with the free doxorubicin released, having both cytotoxic and radiosensitizing properties [37]. There are several studies examining the role of Caelyx given alone [5,11,16] or combined with CDDP and RT [43,44], docetaxel [21], carboplatin [1,3,15,19], and paclitaxel [12,26]. In previous phase I/II trials of CCRT regarding adenocarcinoma of the endometrium [44] and squamous cell carcinoma of the head/neck and lung [43], we found that the combination of CDDP and Caelyx administered concurrently with RT is well tolerated with sufficient activity to justify additional evaluation in clinical trials.…”